BUY HALOTESTIN (FLUOXYMESTERONE) — 5 MG/TABLET, 100 TABLETS
Halotestin contains fluoxymesterone and is supplied as 5 mg uncoated oral tablets. The supplied product information describes fluoxymesterone as an androgen and anabolic steroid medication used for specific medical indications.
Product Information
- Product Name: Halotestin
- Active Ingredient: Fluoxymesterone
- Strength: 5 mg per tablet
- Dosage Form: Tablet
- Route of Administration: Oral
- Molecular Formula: C₂₁H₃₂O₃
- Molecular Weight: 336.45 g/mol
- CAS Number: 76-43-7
- Presentation: 100 uncoated tablets per bottle
- Market Status: Prescription
- Company: Hilma Biocare
Fluoxymesterone is an androgen and anabolic steroid (AAS) medication. According to the supplied product information, it is used in the treatment of low testosterone levels in men, delayed puberty in boys, breast cancer in women, and anaemia.
HALOTESTIN Indications
The supplied information lists the following indications:
In males:
- Replacement therapy for conditions associated with deficiency or absence of endogenous testosterone.
- Primary hypogonadism, whether congenital or acquired.
- Hypogonadotropic hypogonadism, whether congenital or acquired.
- Delayed puberty when definitively established as such and not simply a familial trait.
In females:
- Palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.
Contraindications
The supplied product information lists contraindications including:
- Known hypersensitivity to the drug.
- Male breast carcinoma.
- Known or suspected carcinoma of the prostate gland.
- Known or suspected pregnancy.
- Serious cardiac, hepatic or renal disease.
Side Effects
Reported adverse effects in the supplied information include endocrine and urogenital effects such as menstrual irregularities, inhibition of gonadotropin secretion and virilisation in females, as well as gynaecomastia, excessive penile erections and possible oligospermia in males.
Other reported effects include hirsutism, male-pattern baldness, seborrhoea, acne and fluid and electrolyte retention. Gastrointestinal and hepatic effects may include nausea, cholestatic jaundice and changes in liver function tests. Haematological effects may include suppression of clotting factors and polycythaemia.
Nervous-system effects listed include changes in libido, headache, anxiety, depression and generalised paraesthesia.
Precautions
The supplied information highlights the need for appropriate medical monitoring during treatment. It specifically notes the importance of monitoring for virilisation in women and periodic liver-function testing because of the hepatotoxicity associated with 17-alpha-alkylated androgens.
Additional precautions concern prostate health, priapism, prolonged administration, excessive dosage, tartrazine sensitivity, serum cholesterol and monitoring of bone age in prepubertal males.
Drug Interactions
According to the supplied information, androgens may increase sensitivity to oral anticoagulants and may affect anticoagulant requirements. Concurrent administration with oxyphenbutazone may increase serum oxyphenbutazone levels.
In diabetic patients, androgen therapy may affect blood glucose and insulin requirements. Androgens may also alter thyroid-binding globulin levels, affecting total T4 and resin uptake measurements while free thyroid hormone levels remain unchanged.
Dosage and Administration
The supplied product information states that dosage varies according to the individual, the condition being treated and its severity.
For male hypogonadism, the stated total daily oral dose is 5–20 mg for the majority of patients. For delayed puberty, the information recommends careful dose titration, skeletal monitoring and limiting treatment duration to four to six months. HALOTESTIN HALOTESTIN HALOTESTIN HALOTESTIN HALOTESTIN HALOTESTIN HALOTESTIN HALOTESTIN HALOTESTIN
For advanced inoperable breast carcinoma in females, the supplied information gives a recommended total daily dose of 10–40 mg, administered in divided doses.
Treatment should be undertaken only according to the prescribing information and direction of an appropriately qualified healthcare professional.
Presentation
Halotestin is supplied as 5 mg uncoated tablets, with 100 tablets per bottle.
Storage
Store in a cool, dry place between 15–25°C and protect from direct light.
